SCHEMBL5467196

SCHEMBL5467196

CN1CCC(NC(=O)c2cc3c(Nc4cccc(Cl)c4)ncnc3s2)CC1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 7/20 0.53
AURKB Q96GD4 2/20 0.50
MAPK1 P28482 2/20 0.50
DCLK1 O15075 1/20 0.50
PDPK1 O15530 1/20 0.50
PRKD3 O94806 1/20 0.50
MAP4K4 O95819 1/20 0.50
CHEK2 O96017 1/20 0.50
PIM1 P11309 1/20 0.50
AXL P30530 1/20 0.50
FLT4 P35916 1/20 0.50
FLT3 P36888 1/20 0.50
MAPK9 P45984 1/20 0.50
CSNK1D P48730 1/20 0.50
IRAK1 P51617 1/20 0.50
RPS6KA3 P51812 1/20 0.50
PRKX P51817 1/20 0.50
NEK4 P51957 1/20 0.50
PRKAA1 Q13131 1/20 0.50
STK3 Q13188 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5463018 0.90 ABL1 (0.52) EGFRAURKBMAPK1DCLK1PDPK1
SCHEMBL5255690 0.90 MAPK1 (0.59) EGFRAURKBMAPK1DCLK1PDPK1
SCHEMBL5469689 0.89 MAPK1 (0.49) EGFRAURKBMAPK1DCLK1PDPK1
SCHEMBL5463571 0.88 EGFR (0.50) EGFRAURKBMAPK1DCLK1PDPK1
SCHEMBL5469233 0.88 EGFR (0.60) EGFR
SCHEMBL5465074 0.88 RAB9A (0.55) EGFRAURKBMAPK1DCLK1PDPK1
SCHEMBL5468014 0.88 MAPK1 (0.49) EGFRAURKBMAPK1DCLK1PDPK1
SCHEMBL5462901 0.87 DCLK1 (0.48) EGFRAURKBMAPK1DCLK1PDPK1
SCHEMBL5465060 0.87 EGFR (0.55) EGFRAURKBMAPK1DCLK1PDPK1
SCHEMBL5471146 0.87 EGFR (0.49) EGFRAURKBMAPK1DCLK1PDPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070244133-A1 Thienopyrimidines and Thiazolopyrimidines for Use in Medicine ASTRAZENECA AB (SE) 2007-10-18 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070244133-A1 Thienopyrimidines and Thiazolopyrimidines for Use in Medicine CXCR4, CXCR1, CXCR3 EGFR 4385/4885AURKB 3932/4885MAPK1 1616/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.